Reports not available

Hyperlipidemia and mixed dyslipidemia

Myopathy, hepatotoxicity and renal damage

Hypersenstivity to any of the ingredients

Hyperlipidemia and mixed dyslipidemia

Dosage-

one tablet daily

Pharmacology

Rosuvastatin is a reversible competitive inhibitor of HMGCoA Reductase which prevents or controls the conversion of 30hydroxy-3 -methylglutaryl coenzyme A to mevalonate , a precursor for chloesterol

Rationale for combination- rosuvastatin significantly decreases serum TGs , total cholestrol , LDL-C , non -HDL cholesterol and apoliproprotein B ApoB levels. Fenobibrate a fibric acid derivative is used as anti-hyperlipedemic agent due to the lipid modifying property.

Thus the combination of rosuvastatin and fenofibrate gives the synergistic action in reducing LDL-C and increasing HDL- cholesterol levels